COVID-19 Pandemic Response the Blueprint for Reducing C Difficile Impact
Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.
David M. Poppers, MD: Early Detection for Esophageal Cancer
Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.
Ustekinumab Effective Treating Extra-Intestinal Manifestations of Crohn's Disease
Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.
Brian E. Lacy, MD, PhD: IBS-C Symptoms During COVID-19
A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.
Sheldon Sloan, MD: The Promise of Etrasimod at DDW
Arena Pharmaceuticals expects to move forward with later phase clinical trials testing etrasimod.
Christopher V. Almario, MD: Treatment and Prevalence of Opioid-Induced Constipation
Patients with opioid-induced constipation had more frequent, painful constipation symptoms, compared to those with chronic idiopathic constipation.
David M. Poppers, MD, PhD: A Promising New Esophageal Adenocarcinoma Tool
Direct optical endoscopy are often underutilized in screenings for EAC.
Jordan Axelrad, MD: Role of Infections in Gut Microbiome Signature
Data show patients with IBD and pathogen produced a unique pathogen-specific microbiome.
Evan Dellon, MD: Increasing Biopsies for Esophagitis Diagnosis
Dr. Evan Dellon said up to 8 biopsies for high risk patients could be beneficial in diagnosing different diseases impacting the esophagus.
Joshua Bender: The Impact of COVID-19 on Liver Injuries
COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.
Sucrase Isomaltese Deficiency Prevalent in Patients with IBS-D
Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.
Higher Adalimumab Trough Level Not Linked to Increased Adverse Events in IBD Treatment
Data show adverse events occurred in 6.67% in the cohort of patients with IBD.
Vedolizumab Safe and Effective Treating Inflammatory Bowel Disease
Most of the data on vedolizumab has been limited by small sample sizes and short follow-up.
Charles Owen, MD: An Overview on Cologuard at DDW
About a quarter of Cologuard's ordered by patients are deemed to be inappropriate.
Florian Rieder, MD: Ozanimod as a Treatment for Ulcerative Colitis
Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.
RBX2660 Shows Promise as a C Difficile Treatment
The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.
Acute Pancreatitis Linked to Adverse Outcomes in Patients with Bone Marrow Transplantation
Data show adverse outcomes include increased mortality rates, prolonged hospital stay, and higher hospitalization chargers.
Non-Alcoholic Fatty Liver Disease Associated with Increased Global Burden
Data show global burden of NAFLD increased, while burden of cirrhosis decreased in adolescents and young adults.
Fatigue Linked to Higher Levels of IBD Disease
Ulcerative colitis patients with fatigue are more likely to be unemployed, have moderate or severe disease, and higher Mayo scores.
Significant Correlation Found Between Male Patients with HCV, Advanced Fibrosis
Data show males, patients with high BMI correlated with higher FAST score in HCV care.
Long-Term Ustekinumab Treatment Associated With Improved Quality of Life
Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.
New Initiatives Improve Vaccination Rates in Pediatric Patients with IBD
Data show a 23.5% increase in influenza vaccination rates.
Opioid Treatment, Low BMI Linked to Severe Infection in Patients with IBD
Data show biologic therapy was not associated with ICU admission or death due to infection.
Alpesh Amin, MD: The Challenge of Treating C Difficile Infections
C difficile and sepsis infections can be especially difficult to treat.
High Efficacy Marks for Investigational Treatment for C Difficile Infections
SER-109 resulted in a 73% reduction in relative risk for CDI over 8 weeks.
Similar Outcomes Identified in Comparison of C.Diff of Small Bowel and Colon
Hospitalizations were more likely in patients with CDI of small bowel and Crohn's disease, with worse outcomes noted in patients admitted to ICU.
Christie Teigland, PhD: The Cost of C Difficile and Sepsis
There is a substantial health care cost for CDI patients with sepsis.
C Diff Rates Decreasing Due to Enhanced COVID-19 Measures
In data presented at DDW, researchers find a decrease in hospital-acquired CDI infections in 2020 when compared to 2018 and 2019.
ABX464 as a Treatment for Ulcerative Colitis
Investigators presented information on the 9-month interim results of the ABX464-102 phase 2a examining efficacy in UC patients at DDW 2019.
Rate of Liver Disease Twice as High in Ulcerative Colitis Patients
Study from DDW 2019 found that rates of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nonalcoholic cirrhosis was more than double in patients with UC.